Search Results
Your search for The A matches 34150 pages
Showing 1 - 50
Case 3: Relapsed/Refractory Follicular Lymphoma in the Third Line and Beyond
This is Part 3 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss treatment options...
Case 2: Follicular Lymphoma With Relapse After Rituximab Monotherapy
This is Part 2 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss the...
Case 1: Early Relapsed Follicular Lymphoma
This is Part 1 of Relapsed/Refractory Follicular Lymphoma: Choosing the Right Regimen for the Right Patient, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Loretta Nastoupil, Carla Casulo, and Kami Maddocks discuss the...
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
A new study has shown that AI avatar–based digital patient engagement prior to in-person radiation treatment consultations may enable patients to feel more knowledgeable and less stressed than patients who did not engage with an AI avatar, according to findings presented during the Congress of the...
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Researchers have developed a novel diagnostics tool to detect gene fusions in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with greater sensitivity than standard detection algorithms, according to findings from a study published in The Journal of Molecular Diagnostics. The researchers...
ASCENDE-RT 15-Year Update Shows No Overall Survival Benefit, With ‘Borderline’ Signal for Fewer Deaths
Fifteen-year results from the phase III ASCENDE-RT trial in patients with intermediate- and high-risk localized prostate cancer receiving androgen-deprivation therapy (ADT) and pelvic external-beam radiotherapy (EBRT) show no significant overall survival advantage with a prostate brachytherapy...
Study Shows Potential Missing Patient Information in SEER Database
A significant number of patients with cancer—particularly those with more advanced disease who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information in the Surveillance, Epidemiology, and End Results (SEER)...
Recurrence With Concurrent or Sequential Radiation Dose Escalation to the Surgical Cavity in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Vicini et al, the phase III NRG/RTOG 1005 trial has shown noninferior risk for ipsilateral breast recurrence (IBR) with concurrent vs sequential radiation dose escalation to the surgical cavity in conservative treatment of high-risk early breast...
Patients With IBD May Be at Risk for VTE After Colorectal Cancer Surgery
Patients with inflammatory bowel disease (IBD) may be at a greater risk for postoperative venous thromboembolism (VTE) at least 30 days after surgery for colorectal cancer, according to the results of a large, retrospective study presented at the 2026 Digestive Disease Week Conference. “These...
Ficerafusp Alfa Plus Pembrolizumab: 2-Year Outcomes in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Hanna et al, the 2-year follow-up of the expansion cohort in a phase I/Ib trial indicates persistent benefit of first-line ficerafusp alfa plus pembrolizumab in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell...
Daraxonrasib for Previously Treated RAS-Mutated Pancreatic Cancer
In a phase I/II trial (RMC-6236-001) reported in The New England Journal of Medicine, Wolpin et al identified the safety profile of daraxonrasib and showed activity of the agent in patients with previously treated advanced RAS-mutated pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib (RMC-6236) ...
Study Finds Methylphenidate-Type Psychostimulants May Reduce Cancer-Related Fatigue
A new meta-analysis published by Costa et al in JNCCN—Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants—a class of medication that increases dopamine and norepinephrine availability in the brain—can provide meaningful relief...
Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Past Decade
A new study shows that cases of stage IV breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published by Avila et al in JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly from 9.5...
How Conquering Cancer Is a Team Effort
After finishing her academic studies, Dr. Mittendorf enlisted in the U.S. Air Force—an experience that would propel her into the field of oncology. “My second day on active duty was September 11, 2001,” said Dr. Mittendorf. “I was an attending surgeon at Walter Reed Army Medical Center (now called...
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway modulation–resistant (APMR) (or modulation-sensitive ...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer
On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive early-stage breast cancer. The first indication is for the neoadjuvant treatment of adult...
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA...
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Sigmoidoscopy screening led to reduced incidence of colorectal cancer, though more for men vs women, and a reduced rate of colorectal cancer–related mortality in men, according to findings from the randomized, controlled NORCCAP trial published in the Annals of Internal Medicine. Background and...
Relacorilant Plus Nab-Paclitaxel Improves Overall Survival in Platinum-Resistant Ovarian Cancer
Final overall survival results from the phase III ROSELLA trial showed a statistically and clinically significant survival benefit with the selective glucocorticoid receptor antagonist relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer....
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
An international research team has shown that a specific subtype of diffuse large B-cell lymphoma (DLBCL) is associated with higher mortality risk in women than in men. The study was led by the laboratory of Ari Melnick, MD, Director of the Josep Carreras Leukaemia Research Institute and the Gebroe ...
Early Ovarian Cancer: Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
In a retrospective cohort study reported as a research letter in JAMA Oncology, Matsuo et al found an increasing use of minimally invasive surgery (MIS), an association of MIS with intraoperative capsule rupture, and an association of capsule rupture with poorer survival in patients with early...
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Miszczyk et al found that local therapies alone are associated with “reasonable efficacy” in select patients with locally radiorecurrent prostate cancer. Study Details A literature search through May 2025 was performed to identify...
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?
A systematic review and meta-analysis published in JAMA Network Open found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers. According to Inoue et al, this association appeared to be particularly pronounced in non–small cell lung...
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonged overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer...
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
On May 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor....
FDA Approves Combination Regimen for Newly Diagnosed AML
On May 13, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine tablets (Inqovi) plus venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or who have comorbidities that preclude them from...
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
Hundreds of thousands of people diagnosed with cancer are still alive today, but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those diagnosed today to carry a germline...
Inherited Long Telomeres May Increase the Risk of Lymphoid Cancers
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically “younger” for longer than normal, predisposing ...
Addition of Toripalimab to Perioperative Chemotherapy in Locally Advanced Gastric or Gastroesophageal Junction Cancer
In an update of a Chinese phase II trial (NEOSUMMIT-01) reported in the Journal of Clinical Oncology, Nie et al found that the addition of the anti–PD-1 antibody toripalimab to perioperative chemotherapy improved 3-year event-free and overall survival in patients with locally advanced gastric or...
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response (pCR) in almost half of patients with stage I to III mismatch repair–deficient (dMMR) colon...
Inflammatory Breast Cancer: Blood-Based Biomarkers Identified
Researchers have identified blood-based biomarkers in tumors, peripheral blood cells, and plasma that may help to differentiate between inflammatory breast cancer and non–inflammatory breast cancer, according to findings published in Science Advances. “These findings provide new insights into...
New Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma
A clinical whole-genome sequencing test for patients with multiple myeloma, JAYseq, has been launched at the Translational Genomics Research Institute (TGen). “The launch of JAYseq represents a meaningful step in oncology testing, one that allows physicians to make a more precise treatment...
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
A new urine test performed better than prostate specific antigen (PSA)-based testing and magnetic resonance imaging (MRI) for monitoring patients with low-risk prostate cancer on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% ...
Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults
In a cohort study reported in JAMA Oncology, Fox et al found that approximately half of older patients with metastatic non–small cell lung cancer (NSCLC) have received systemic therapy in the United States in recent years. Study Details The population-based study used linked Surveillance...
B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD
In a phase II trial reported in the Journal of Clinical Oncology, Cutler et al found that early B-cell depletion with obinutuzumab reduced the risk of corticosteroid-requiring chronic graft-vs-host disease (GVHD) in allogeneic transplant recipients at increased risk of chronic GVHD. Study Details...
Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival
In a patient-level meta-analysis reported in The Lancet, the Early Breast Cancer Trialists’ Collaborative Group found that ovarian function suppression (OFS) with ablation or drugs was associated with reduced 15-year risk of recurrence or death irrespective of chemotherapy or tamoxifen use in...
First Virtual Cancer Clinic to Receive ASCO Certified Status
ASCO has certified its first virtual cancer clinic from Color, a company that owns and operates a nationwide, oncologist-led Virtual Cancer Clinic, serving employer, union, health plan, and public sector populations. The ASCO Certified status indicates that the virtual practice meets a high set of...
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic NRG1-Mutated Cholangiocarcinoma
The U.S. Food and Drug Administration (FDA) approved the HER2- and HER3-directed bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. The...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Patient Care Is Not What We Do, But What Patients Perceive
In modern health care, patient care is often defined by clinical actions such as diagnoses made, treatments delivered, and protocols followed. Clinicians are trained to prioritize technical accuracy, evidence-based interventions, and measurable outcomes. However, an equally critical and often...
Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book
ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book. Dr. Hsu is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF), where he has served in numerous educational leadership roles. Since 2018,...
New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer
ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years.1 “Despite a rather rapidly evolving field of targeted and nontargeted systemic agents in the management of...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
ARS Honors Thomas Buchholz, MD, With 2026 Gold Medal Award
The American Radium Society (ARS) presented its 2026 Gold Medal Award to Scripps Cancer Center Medical Director Thomas Buchholz, MD, at its Annual Meeting in Newport Beach, California. The Gold Medal Award is the organization’s highest honor for a member who has made significant contributions to...
From Hawaii to Health AI: A Career at the Intersection of Oncology, Data Science, and Clinical Knowledge
Raised in Lahaina, Hawaii, before wildfires destroyed much of the small tourist town in 2023, Travis Zack, MD, PhD, took an atypical path into medicine. His journey has been shaped by family, mentors, a personal experience with cancer, and a growing interest in how artificial intelligence (AI) can...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Long-Term Risks Revealed for Older Survivors of Childhood Cancers
Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report published in the Journal of Clinical Oncology.1 When compared with the general population or sibling ...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on patient anxiety and clinician workload. The performance of the model was assessed in a...
